Drugs / Daglutril
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00160225 | Jul 2005 → ? | hypertensive disorder | Solvay Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT00160212 | Dec 2004 → ? | hypertensive disorder | Solvay Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daglutril | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00160212 ↗ |
| Known as | Daglutrilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989794 ↗ |
| Known as | SLV-306 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989794 ↗ |
| Action | Inhibit | “We tested the effects of treatment of such patients with daglutril, a combined endothelin-converting enzyme and neutral endopeptidase inhibitor.” PMID 24622263 ↗ Jun 2013 |
| Modality | Small molecule | — CHEMBL3989794 ↗ |
| Target | ECE1 | “Endothelin-converting enzyme 1 inhibitor” CHEMBL3989794 ↗ |
| Target | MME | “Neprilysin inhibitor” CHEMBL3989794 ↗ |